LRRK2 and Parkinson disease: 5′-deoxyadenosinecoamin (AdoCbl), a physiological form of VB12, inhibits LRRK2 kinase activity by disrupting LRRK2 dimerization and reduces its neurotoxicity in cultured primary neurons and Drosophila PD models [35].